<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143000</url>
  </required_header>
  <id_info>
    <org_study_id>Swedish MPA nr. 151:2004/3458</org_study_id>
    <secondary_id>Ethical Committee nr. Ö 763/03</secondary_id>
    <nct_id>NCT00143000</nct_id>
  </id_info>
  <brief_title>Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3</brief_title>
  <official_title>A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NORDynamIC Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NORDynamIC Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate that the efficacy of peginterferon&#xD;
      alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic&#xD;
      hepatitis C virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective of the Study: To demonstrate that the efficacy of peginterferon alfa-2a&#xD;
      40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C&#xD;
      (CHC) virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (&lt;50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT measurements at 24 weeks post completion of the 12 or 24 week treatment period.</measure>
  </secondary_outcome>
  <enrollment type="Actual">392</enrollment>
  <condition>Hepatitis C Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a 40KD and Ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients ≥18 years of age&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test&#xD;
&#xD;
          -  Serum HCV-RNA quantifiable at &gt;600 IU/mL by the Roche AMPLICOR HCV MONITOR® Test,&#xD;
             v2.0.&#xD;
&#xD;
          -  HCV genotype 2 or 3 infection confirmed within the past 2 years preceding the&#xD;
             initiation of test drug dosing.&#xD;
&#xD;
          -  Elevated serum ALT activity documented on at least one occasion within the past 12&#xD;
             months preceding the initiation of test drug dosing.&#xD;
&#xD;
          -  Chronic liver disease consistent with chronic hepatitis C infection on a biopsy&#xD;
             (obtained within the past 2 years) as judged by a local pathologist.&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh Grade A clinical classification)&#xD;
&#xD;
          -  Patients with cirrhosis or transition to cirrhosis must have an abdominal ultrasound,&#xD;
             CT scan, or MRI scan without evidence of hepatocellular carcinoma and a serum AFP &lt;100&#xD;
             ng/mL within 2 months of randomization&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using effective&#xD;
             contraception during treatment and during the 6 months after treatment end&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  IFN or ribavirin therapy at any previous time&#xD;
&#xD;
          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) *6 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Any investigational drug ≤6 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  HCV genotype 1, 4, 5 or 6 infection.&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, anti-HIV Ab&#xD;
&#xD;
          -  Evidence of a medical condition associated with chronic liver disease other than HCV&#xD;
             (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver&#xD;
             disease, toxin exposures)&#xD;
&#xD;
          -  History or other evidence of decompensated liver disease&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Serum creatinine level &gt;2 mg/dl (&gt;124 µmol/L) or creatinine clearance &lt;50 ml/minute at&#xD;
             screening&#xD;
&#xD;
          -  Severe psychiatric disease, especially depression, as judged by the treating&#xD;
             physician.&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, severe chronic pulmonary disease&#xD;
             associated with functional limitation, severe cardiac disease, major organ&#xD;
             transplantation or other evidence of severe illness, malignancy, or any other&#xD;
             conditions which would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study&#xD;
&#xD;
          -  Thyroid dysfunction not adequately controlled (TSH and T4 levels out of normal range)&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically&#xD;
             relevant ophthalmological disorder due to diabetes mellitus or hypertension&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) in accordance with&#xD;
             local therapeutic traditions.&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Ηemoglobin &lt;11.3 g/dL (&lt;7.0 mmol/L) in women or &lt;12.9 g/dL (&lt;8.0 mmol/L) in men at&#xD;
             screening.&#xD;
&#xD;
          -  Any patient with an increased baseline risk for anemia (e.g. thalassemia,&#xD;
             spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically&#xD;
             problematic&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Norkrans, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Göteborg University</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>April 4, 2008</last_update_submitted>
  <last_update_submitted_qc>April 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2008</last_update_posted>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Genotype 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

